Oncology Micro learning - Video, slides and more 

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

Prof. Dr Peter R. Galle

Prof. Dr Peter R. Galle
Prof. Aiwu Ruth He

Prof. Aiwu Ruth He
Publication Date

Apr 2023

info Summary and next episodes download Downloadable resources

In Module 1 of this micro learning, developed by experts Prof. Peter R. Galle and Dr Aiwu Ruth He, you'll learn about the safety and efficacy of immunotherapy (IO) for hepatocellular carcinoma (HCC) and how to implement IO treatments for patients with HCC in clinical practice.

The content includes a short animated video, downloadable resources, and an assessment to test your knowledge.

When you're ready, move on to Module 2: The Use of Immunotherapy in HCC: In-depth Subgroup Analyses and Challenges.

 

Efficacy of IO for HCC

Learn how to:

  • Recognise the efficacy of IO and IO combinations
  • Understand the survival curve when assessing IO treatment
  • Know where IO and IO combinations sit in the treatment landscape for patients with HCC

 

Safety of IO for HCC

Learn how to:

  • Recognise the immune-related adverse events (irAEs) and potential additive or synergistic toxicities associated with IO combinations
  • Know how to identify and manage these AEs early on

 

Clinical Takeaways

 

  • IO, and in particular IO combinations, are effective treatments for patients with advanced HCC

  • Survival analysis for IO treatment shifts from median overall survival (OS) to landmark analysis

  • IO and IO combinations may result in inflammatory side effects, known as irAEs. Most of these AEs can be treated with steroids

  • Recognise the efficacy of IO and IO combinations 
    • Understand the survival curve when assessing IO treatment 
    • Know the place of IO and IO combinations in the treatment landscape for patients with HCC 
  • Recognise the immune-related adverse events (irAEs), and potential additive or synergistic toxicities associated with IO combinations 
    • Know how to early identify and manage these AEs 
  • Be able to implement IO treatments for patients with HCC in clinical practice 

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

 

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

 

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

 

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Prof. Aiwu Ruth He has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Boston Scientific, Eisai, Genentech and Merck.
pdf Flashcard - pdf Download clock
pdf Slides - pdf Download clock
pdf Slides - PPT Download clock

In Module 1 of this micro learning, developed by experts Prof. Peter R. Galle and Dr Aiwu Ruth He, you'll learn about the safety and efficacy of immunotherapy (IO) for hepatocellular carcinoma (HCC) and how to implement IO treatments for patients with HCC in clinical practice.

The content includes a short animated video, downloadable resources, and an assessment to test your knowledge.

When you're ready, move on to Module 2: The Use of Immunotherapy in HCC: In-depth Subgroup Analyses and Challenges.

 

Efficacy of IO for HCC

Learn how to:

  • Recognise the efficacy of IO and IO combinations
  • Understand the survival curve when assessing IO treatment
  • Know where IO and IO combinations sit in the treatment landscape for patients with HCC

 

Safety of IO for HCC

Learn how to:

  • Recognise the immune-related adverse events (irAEs) and potential additive or synergistic toxicities associated with IO combinations
  • Know how to identify and manage these AEs early on

 

Clinical Takeaways

 

  • IO, and in particular IO combinations, are effective treatments for patients with advanced HCC

  • Survival analysis for IO treatment shifts from median overall survival (OS) to landmark analysis

  • IO and IO combinations may result in inflammatory side effects, known as irAEs. Most of these AEs can be treated with steroids

  • Recognise the efficacy of IO and IO combinations 
    • Understand the survival curve when assessing IO treatment 
    • Know the place of IO and IO combinations in the treatment landscape for patients with HCC 
  • Recognise the immune-related adverse events (irAEs), and potential additive or synergistic toxicities associated with IO combinations 
    • Know how to early identify and manage these AEs 
  • Be able to implement IO treatments for patients with HCC in clinical practice 

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

 

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

 

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

 

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Prof. Aiwu Ruth He has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Boston Scientific, Eisai, Genentech and Merck.
Programme summary
Take the micro learning now
Other episodes of this series
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

 Current Module
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 2: In-depth Subgroup Analyses and Challenges
The expanding role of immunotherapy in HCC

The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Endorsement
AASLD
Digestive Cancers Europe
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Other episodes of this series
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

 Current Module
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 2: In-depth Subgroup Analyses and Challenges
The expanding role of immunotherapy in HCC

The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Endorsement
AASLD
Digestive Cancers Europe
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

A novel therapeutic framework 

Experts
Dr Komal Jhaveri, Oncology Brothers (Moderators)
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
BREAST CANCER CONNECT PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca 
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
NET CONNECT
Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
patient-support Patient Support

Episode

1

of 2

episode
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
NET CONNECT
Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
ESDO
Digestive Cancers Europe
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education
GI CONNECT PRECISION ONCOLOGY CONNECT GI NURSES CONNECT
Educational programme supported by an Independent Educational Grant from Amgen.
Explore all programmes